Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...

Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.